A detailed history of Hsbc Holdings PLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 15,286 shares of VKTX stock, worth $757,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,286
Previous 13,746 11.2%
Holding current value
$757,879
Previous $728,000 32.83%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $76,753 - $108,523
1,540 Added 11.2%
15,286 $967,000
Q2 2024

Aug 12, 2024

BUY
$47.39 - $80.2 $437,409 - $740,246
9,230 Added 204.38%
13,746 $728,000
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $78,578 - $426,762
4,516 New
4,516 $370,000
Q2 2020

Aug 14, 2020

SELL
$4.35 - $8.08 $51,691 - $96,014
-11,883 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$3.45 - $7.95 $40,996 - $94,469
11,883 New
11,883 $56,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.8B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.